CHRIS A. RALLIS - Corporate Board Profile

TENAX THERAPEUTICS, INC.

Filing Date	Source Excerpt
2012-08-01	Chris A. Rallis has served as a director since December 2011. Mr. Rallis serves on the Audit Committee. 2012 Director Compensation: Chris A. Rallis - Total: $26,878.
2013-03-28	Chris A. Rallis Amount and Nature of Beneficial Ownership 25,754 Percent *
2013-11-04	Chris A. Rallis has served as a director since December 2011. Mr. Rallis serves on the Audit Committee. 2013 Director Compensation table shows total compensation of $69,000.
2014-02-04	2013 Director Compensation Director Fees Earned or Paid in Cash ($) Option Awards ($) Stock Awards ($) All Other Compensation ($) Total ($) Chris A. Rallis(1)(2) 35,750 — 33,250 — 69,000
2014-08-12	Chris A. Rallis has served as a director since December 2011. Mr. Rallis serves as a member of the Audit Committee. 2014 Director Compensation: Chris A. Rallis Fees Earned or Paid in Cash $33,500, Option Awards $34,500, Total $68,000.
2015-08-17	Chris A. Rallis has served as a director since December 2011. Mr. Rallis serves as a member of the Audit Committee. 2015 Director Compensation table shows total compensation of $89,607.
2016-04-26	Chris A. Rallis has served as a director since December 2011. Mr. Rallis serves as a member of the Audit and Compliance Committee. Transition Period 2015 Director Compensation: $56,596 total.
2017-04-28	Chris A. Rallis has served as a director since December 2011. Mr. Rallis serves as a member of the Audit and Compliance Committee.
2018-01-16	With respect to Mr. Rallis, includes 2,565 shares of common stock subject to warrants and 39,798 shares of common stock subject to options that are vested, vesting, exercisable or convertible, as applicable, within 60 days of December 28, 2017;
2018-04-20	Chris A. Rallis has served as a director since December 2011. Mr. Rallis serves as a member of the Audit and Compliance Committee.
2019-04-19	Chris A. Rallis has served as a director since December 2011. Since January 2008, Mr. Rallis has served as an Executive-in-Residence at Pappas Capital, a life science venture capital firm based in Durham, NC. From April 2006 until June 2007, he was President and Chief Executive Officer of ImmunoBiosciences, Inc., a vaccine technology company formerly located in Raleigh, NC. He has served as a consultant for Duke University and Panacos Pharmaceuticals, Inc., and is the former President and Chief Operating Officer of Triangle Pharmaceuticals, Inc. (“Triangle”), which was acquired by Gilead Sciences in January 2003 for approximately $465 million. While at Triangle, he participated in 11 equity financings generating gross proceeds of approximately $500 million. He was also primarily responsible for all business development activities which included a worldwide alliance with Abbott Laboratories and the in-licensing of 10 compounds. Earlier, he served in various business development and legal management roles with Burroughs Wellcome, Co. Mr. Rallis serves on the boards of Fennec Pharmaceuticals, a publicly traded company, and Aeolus Pharmaceuticals (which has ceased operations). He received his A.B. degree in economics from Harvard College and a J.D. from Duke University. We believe that Mr. Rallis’ strong background in raising capital, business development and operations developed through his leadership at other companies operating within the biomedical industry qualifies him to serve on our Board. Mr. Rallis serves as a member of the Audit and Compliance Committee and the Compensation Committee. Fiscal 2018 Director Compensation: Fees Earned or Paid in Cash $55,000, Option Awards $2,624, Total $57,624.
2020-04-29	Chris A. Rallis has served as a director since December 2011. Mr. Rallis serves as a member of the Audit and Compliance Committee and the Compensation Committee. Fiscal 2019 Director Compensation: Chris A. Rallis - Fees Earned or Paid in Cash: $57,500, Option Awards: $735, Total: $58,235.